According to the report, the lead authors on the 13 original studies of InFuse received payments ranging from $1.7 million to $64 million and Medtronic's marketing employees were co-authors and co-editors on the studies.
NASS strongly advocates that data published in scientific journals and shared at medical conferences is accurate, complete and transparent.
More Articles on Spine Surgery:
Spine Surgery QALY Gains $56,592 Over Medical Management for Spinal Stenosis
10 Most Important Qualities for Spine Surgeon Leaders Today
ISASS Joins Medical Societies Petition to Eliminate SGR
NASS Responds to US Senate Finance Committee Report on Infuse FeaturedWritten by Laura Miller | October 25, 2012
The recent investigation by the U.S. Senate Committee on Finance into the surgeon/industry relationships, scientific publishing and marketing of Medtronic's bone morphogenic protein product InFuse was released earlier this week and confirms reports from the June 2011 issue of the North American Spine Society's The Spine Journal.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.